Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Biotechnology

Healthcare
$23.40 +0.05%

+$0.02 today

Market cap
$1.12B
Beta
0.98
P/E (TTM)
-16.2
EPS (TTM)
-$2.27
52W Low $10.51High $42.27

Volume 0.73M

Average 0.33M

RAPP Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 29.7% from a year ago

Common stock stood at $48K at the end of Q1 FY2026, up 29.7% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +15.7% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +29.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$48K+0.0% QoQ
Last fiscal yearDec 2025
$48K+29.7% YoY
Year agoMar 2025
$37K+29.7% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.7%——
1 year+29.7%——
3-year CAGR+15.7%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
48K USD
Year-over-year change
+29.7%
3-year CAGR
+15.7%

Common Stock vs competitors

How RAPP compares with its peers on the latest reported figures

  • RAPP's Mar 2026 common stock of $48K is the 2nd highest of the 10 companies compared; the peer median is $5K.
  • Its year-over-year change of +29.7% is the 4th highest of 9, against a peer median of +9.8%.
  • Common stock amounts to 0.0% of total assets for RAPP, versus a peer median of 0.0%.
RAPP Competitors Peer median
Common Stock for RAPP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CGTXCognition Therapeutics, Inc.Mar 2026$90K +45.2%+45.9%0.2%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$48K +29.7%+15.7%0.0%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$37K +42.3%+45.5%0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$18K +12.5%+78.3%0.0%
PRAXPraxis Precision Medicines, Inc.Sep 2026$15K +7.1%+44.2%0.0%
AXSMAxsome Therapeutics, Inc.Jun 2026$5K +0.0%+7.7%0.0%
MPLTMapLight Therapeutics, Inc.Mar 2026$5K ——0.0%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$3K +200.0%+44.2%0.0%
ANROAlto Neuroscience, Inc.Mar 2026$3K +0.0%+44.2%0.0%
ACADACADIA Pharmaceuticals Inc.Sep 2026$0 -100.0%+0.0%0.0%
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding RAPP) $5K+9.8%+44.2%0.0%

Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents31.16M70.17M56.81M52.65M
Short-term Investments077.31M248.48M437.89M
Net Receivables0000
Inventory0000
Other Current Assets03.39M4.52M8.02M
Total Current Assets31.27M150.87M309.8M498.56M
Property, Plant & Equipment (Net)335K4M4.97M12.89M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets0551K160K985K
Total Non-current Assets335K4.55M5.13M13.87M
Total Assets31.6M155.42M314.93M512.43M
Account Payables1.45M2.5M1.95M4.19M
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities02.41M3.71M7.12M
Total Current Liabilities1.66M8.8M8.77M19.05M
Long-term Debt10.44M008.73M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities0170.78M00
Total Non-current Liabilities10.44M172.25M739K8.73M
Total Liabilities12.1M181.06M9.51M27.78M
Common Stock31K4K37K48K
Retained Earnings(10.65M)(45.44M)(123.75M)(235.23M)
Accumulated OCI04K(522K)546K
Other Stockholders Equity0000
Minority Interest0000
Total Equity19.51M(25.63M)305.43M484.65M
Total Debt10.44M2.15M1.48M11.48M
Net Debt(20.72M)(68.02M)(55.33M)(41.16M)

Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Intrinsic Alpha fair value

Locked

Current Price

$23.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.